Dementia and Neurodegeneration Mental and Behavioural Disorders
Conditions
Interventions
Five of the practices will deliver SPLENDID social prescribing and five will continue to provide usual care (i.e. social prescribing at usual rate). Social prescribing link workers at intervention pra
Sponsors
University of East Anglia
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: GP practices: To participate in the study, site Principal Investigators (PI) and sites must fulfil a set of criteria that have been agreed by the SPLENDID Programme Management Group (PMG) and that are defined below: 1. GP practice is willing and able to adopt the intervention into routine care. 2. At least one SPLW that provides social prescribing for patients registered at the surgery, willing to take part in the study. 3. A named clinician who is willing and appropriate to take Principal Investigator (PI) responsibility. 4. Practice staff who are willing and have sufficient workload capacity to recruit patients and enter data into the study database. Social Prescribing Link Worker: 1. Involved in the social prescribing pathway for patients registered at the practice. 2. Willing to be trained to deliver SPLENDID. People living with dementia (PLWD) invited to SPLENDID social prescribing (intervention practices): 1. Aged >= 18 years at time of invitation to SPLENDID. 2. Clinical diagnosis of dementia of any subtype within the last 2 years. 3. Living at home (not in a care home). PLWD inclusion criteria to take part in the Patient Reported Outcome Measures (PROMs) study. In addition to the inclusion criteria above, PLWD must meet the following criteria to be invited to provide PROMs: 1. Able to communicate in English sufficiently well to answer questionnaires, as assessed by the research nurse or equivalent during the consent process 2. Has mental capacity to provide informed consent to the PROMS study OR has a consultee 3. Has mental capacity to answer questionnaires Carers: 1. Aged >= 18 years at time of consent. 2. Able to communicate in English sufficiently well to complete the questionnaires, as assessed by the research nurse or equivalent during the consent process. 3. Cares/supports the PLWD providing PROMs. 4. Has mental capacity to provide informed consent and answer questionnaires. 5. Cares/supports the PLWD providing PROMs.
Exclusion criteria
Exclusion criteria: GP Practices: GP practices without SPLWs for the duration of the study. Social Prescribing Link Worker: Working at another GP practice taking part in the study which is randomised to a different arm. PLWD for Patient Reported Outcome Measures (PROMs) study: 1. Unable to communicate even with augmentative and alternative communication support. 2. Awaiting a move to residential care. 3. Undergoing end of life care, life expectancy < 6 months. 4. Taking part in another interventional dementia study. 5. Has already taken part in another work package in the SPLENDID research programme. Carers: 1. Reports feeling overburdened or has severe, unstable (mental or physical) health problems. 2. Diagnosis or health condition that may impair their ability to complete questionnaires, as assessed by the research nurse or equivalent during the consent process. 3. Taking part in another interventional dementia study. 4. Paid, professional carer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of sites (GP practice) recruited over the course of the study measured using study records at end of study;Feasibility and acceptability of SPLENDID training and delivery amongst social prescribing link workers (SPLW) measured using the number of Social Prescribing Link Workers (SPLW) who consent to take part in study and the number of SPLW who complete SPLENDID training at over the course of the study;Feasibility and acceptability of SPLENDID social prescribing amongst people living with dementia (PLWD) measured using the number of People Living With Dementia (PLWD) invited to SPLENDID, number (and percentage) who agree to receive SPLENDID, number (and percentage) who complete SPLENDID at over the course of the study;Percentage of PLWD who discontinue SPLENDID social prescribing measured using patient records at end of study;PLWD and carer recruitment and attrition rates of the Patient Reported Outcome Measures (PROMS) study measured using records at over the course of the study;Ability to collect data (including PROMS, routine data from medical records and process evaluation) to address outcomes for the definitive study measured using percentage of PLWD participants who consent to PROMs study, who remain in the study and provide valid outcome measure data and health-economic measures at 14-week follow-up, completeness of PROMs data, completeness of routine data collected from medical records for PLWD, proportion of practice staff (e.g. SPLWs who take part in process evaluation activities (interviews, observations), number of SPLENDID sessions observed, number of PLWD who agree to talk about their sessions with a researcher and number of interviews with practice staff conducted at over the course of the study;Inform iterative refinement of the SPLENDID social prescribing pathway and intervention for the definitive study measured using an estimation of the mean, standard deviation and intra-class correlation coefficient (ICC) for the proposed primary outcome | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographics measured using data collected at baseline;Cognition measured using the Montreal Cognitive Assessment 5 minute/Telephone (T-MoCA) at baseline and 14-week follow-up;The levels of engagement and independence in individuals with dementia measured using the Engagement and Independence in Dementia Questionnaire (EID-Q) at baseline and 14-week follow-up;Quality of life for individuals with mild to moderate dementia measured using the Bath Assessment of Subjective Quality of Life in Dementia (BASQID) at baseline and 14-week follow-up;Hope and resilience experienced by individuals with dementia measured using the Positive Psychology Outcome Measure (PPOM) at baseline and 14-week follow-up;Mental well-being measured using the World Health Organization-Five Well-Being Index (WHO-5) at baseline and 14-week follow-up;For intervention group only: understand and prioritise what the PLWD would like support with measured using the Measuring My Concerns and Wellbeing (MYCaW) is used by the SPLW at at the initial SPLW session;Health-related quality of life measured using the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) at baseline and 14-week follow-up;Quality of life measured using the ICEpop Capability measure for older people aged =65 (ICECAP-O) at baseline and 14-week follow-up;Health and social care service use by the PLWD measured using the Client Service Receipt Inventory (CSRI) at baseline and 14-week follow-up | — |
Countries
United Kingdom
Contacts
Public ContactJane Cross
Outcome results
None listed